Abstract Number: 1592 • ACR Convergence 2023
Memantine Attenuates the Development of Osteoarthritis by Blocking NMDA Receptor Mediated Calcium Overload and Chondrocyte Senescence
Background/Purpose: Memantine is an FDA proved drug utilized for the treatment of dementia and exerts its function by blocking the NMDA (N-methyl-D-aspartate) receptor, a calcium…Abstract Number: 1628 • ACR Convergence 2023
The Impact of Cardiovascular and Cerebrovascular Disease on the Risk of Dementia in Rheumatoid Arthritis. a Mediation Analysis
Background/Purpose: Alzheimer's disease and related dementias have an immense disease burden, with predicted continuous increase in incidence and prevalence. Systemic inflammation plays a major role…Abstract Number: 009 • 2023 Pediatric Rheumatology Symposium
The Bridge to Adult Care from Childhood for Young Adults with Rheumatic Disease (BACC YARD) Program, a Pediatric-to-Adult Rheumatology Transition Program
Background/Purpose: Children with chronic rheumatic conditions age and require transfer to adult rheumatologists for continued care. The transition period from pediatric to adult-oriented care is…Abstract Number: 0268 • ACR Convergence 2022
Risks of Mortality in Elderly-onset Rheumatoid Arthritis: Analysis from the TRA Clinical Electronic Registry
Background/Purpose: Patients with rheumatoid arthritis (RA) were associated with increased mortality rate. Our study aimed to investigate the risk factors associated with all causes of…Abstract Number: 0281 • ACR Convergence 2022
Clinical Outcomes of Filgotinib in Patients with RA Aged ≥65 Years: A Post Hoc Subgroup Analysis of Phase 2 and 3 Clinical Trials and Ongoing Long-Term Extensions
Background/Purpose: Filgotinib (FIL) is a Janus kinase 1 preferential inhibitor approved for the treatment of moderate to severe active RA.1 It was previously reported that…Abstract Number: 0529 • ACR Convergence 2022
Complex Relationships Between Inflammation and Clonal Hematopoiesis in Systemic Vasculitis
Background/Purpose: Clonal hematopoiesis of indeterminate potential (CHIP) is defined by somatic mutations in a set of genes commonly associated with myeloid neoplasms in an otherwise…Abstract Number: 0574 • ACR Convergence 2022
Osteoporosis in Elderly Men; An Underestimated and Underdiagnosed Morbid Entity
Background/Purpose: 20-25% of osteoporosis-related fractures occur in men and the mortality of osteoporotic fractures is higher in men [1]. Nevertheless, no uniform consensus exists for…Abstract Number: 0734 • ACR Convergence 2022
Comfort Levels and Practice Patterns for Osteoporosis-Related Care Among Persons Living with HIV in Peru: A National Physician Survey
Background/Purpose: As they age, persons living with HIV (PLWH) are at increased risk for osteoporosis due to chronic infection and antiretroviral therapies (ART). In Peru,…Abstract Number: 0837 • ACR Convergence 2022
Providers’ Adoption of 2017 Guidelines on DMARD Use Perioperatively for Elective Total Hip and Knee Arthroplasty at a Single Academic Center
Background/Purpose: Rate of prosthetic joint infection (PJI) after total joint arthroplasty (TJA) is higher in patients with rheumatic conditions than in patients with OA. Our…Abstract Number: 1196 • ACR Convergence 2022
Interaction of Cumulative Inflammation with Smoking and Lipids in Risk Modification of Dementia Among Patients with Rheumatoid Arthritis: A Population-based Cohort Study
Background/Purpose: Patients with rheumatoid arthritis (RA) have increased risk of developing dementia. Systemic inflammation is implicated in the pathogenesis of cognitive decline. However, the association…Abstract Number: 1327 • ACR Convergence 2022
Immune Cell Subsets and Risk of Incident Hip Fracture in Older Adults: The Cardiovascular Health Study
Background/Purpose: Cell-mediated immunity may play a role in osteoporosis development. Fracture is the major consequence of osteoporosis. Thus, cell-mediated immunity may impact fracture risk. We…Abstract Number: 1396 • ACR Convergence 2022
Risk of Hospitalized Infections in Older Elderly Rheumatoid Arthritis Patients Treated with Biological/Targeted Synthetic DMARDs: Evaluation Using Data from a Japanese Claims Database
Background/Purpose: Safety evidence of biological or targeted synthetic DMARDs (b/tsDMARDs) is still insufficient in older elderly ( >=75 years old (y/o)) patients with rheumatoid arthritis…Abstract Number: 1460 • ACR Convergence 2022
Neuropsychiatric Lupus in Late and Early Onset Systemic Lupus Erythematosus Patients: A Systemic Review and Meta-analysis
Background/Purpose: The diagnosis of neuropsychiatric lupus (NPSLE) is challenging due to its variegated presentation, absence of diagnostic biomarkers and radiological imaging. The NPSLE is further…Abstract Number: 1481 • ACR Convergence 2022
Dementia in Adults with Systemic Lupus Erythematosus 65 Years of Age and Above: A National Administrative Claims Data Analysis
Background/Purpose: Systemic lupus erythematosus (SLE) has been associated with increased risk of dementia relative to age-matched comparators without systemic rheumatic disease (SRD) in non-US-based samples…Abstract Number: 0008 • ACR Convergence 2022
CD11c+ T-Bet+ B Cells Traffic to Human Bone Marrow
Background/Purpose: CD11c+ age/autoimmunity-associated B cells (ABC) are associated with autoantibody producing cells and disease flare in systemic lupus erythematosus. ABC were initially identified in aged…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 11
- Next Page »